|
1
|
Hatzaras I, Bischof DA, Fahy B, Cosgrove D
and Pawlik TM: Treatment options and surveillance strategies after
therapy for hepatocellular carcinoma. Ann Surg Oncol. 21:758–766.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Morise Z, Kawabe N, Tomishige H, Nagata H,
Kawase J, Arakawa S, Yoshida R and Isetani M: Recent advances in
liver resection for hepatocellular carcinoma. Front Surg. 1:212014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chan TH, Lin CH, Qi L, Fei J, Li Y, Yong
KJ, Liu M, Song Y, Chow RK, Ng VH, et al: A disrupted RNA editing
balance mediated by ADARs (Adenosine DeAminases that act on RNA) in
human hepatocellular carcinoma. Gut. 63:832–843. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Raveh E, Matouk IJ, Gilon M and Hochberg
A: The H19 Long non-coding RNA in cancer initiation, progression
and metastasis-a proposed unifying theory. Mol Cancer. 14:1842015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu AX, Kang YK, Rosmorduc O, Evans TR,
Santoro A, Ross P, Gane E, Vogel A, Jeffers M, Meinhardt G and Peña
CE: Biomarker analyses of clinical outcomes in patients with
advanced hepatocellular carcinoma treated with sorafenib with or
without erlotinib in the SEARCH trial. Clin Cancer Res.
22:4870–4879. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ikeda M, Shimizu S, Sato T, Morimoto M,
Kojima Y, Inaba Y, Hagihara A, Kudo M, Nakamori S, Kaneko S, et al:
Sorafenib plus hepatic arterial infusion chemotherapy with
cisplatin versus sorafenib for advanced hepatocellular carcinoma:
Randomized phase II trial. Ann Oncol. 27:2090–2096. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lencioni R, Chen XP, Dagher L and Venook
AP: Treatment of intermediate/advanced hepatocellular carcinoma in
the clinic: How can outcomes be improved? Oncologist. 15 (Suppl
4):S42–S52. 2010. View Article : Google Scholar
|
|
8
|
Finn RS, Zhu AX, Farah W, Almasri J, Zaiem
F, Prokop LJ, Murad MH and Mohammed K: Therapies for advanced stage
hepatocellular carcinoma with macrovascular invasion or metastatic
disease: A systematic review and meta-analysis. Hepatology.
67:422–435. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carmeliet P, Dor Y, Herbert JM, Fukumura
D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R,
Maxwell P, et al: Role of HIF-1alpha in hypoxia-mediated apoptosis,
cell proliferation and tumour angiogenesis. Nature. 394:485–490.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eyries M, Siegfried G, Ciumas M, Montagne
K, Agrapart M, Lebrin F and Soubrier F: Hypoxia-induced apelin
expression regulates endothelial cell proliferation and
regenerative angiogenesis. Circ Res. 103:432–440. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Semenza GL: Hypoxia-inducible factor 1
(HIF-1) pathway. Sci STKE. 2007:cm82007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang H, Lu H, Xiang L, Bullen JW, Zhang
C, Samanta D, Gilkes DM, He J and Semenza GL: HIF-1 regulates CD47
expression in breast cancer cells to promote evasion of
phagocytosis and maintenance of cancer stem cells. Proc Natl Acad
Sci USA. 112:E6215–E6223. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Botusan IR, Sunkari VG, Savu O, Catrina
AI, Grünler J, Lindberg S, Pereira T, Ylä-Herttuala S, Poellinger
L, Brismar K and Catrina SB: Stabilization of HIF-1alpha is
critical to improve wound healing in diabetic mice. Proc Natl Acad
Sci USA. 105:19426–19431. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim DH, Sung B, Kim JA, Kang YJ, Hwang SY,
Hwang NL, Suh H, Choi YH, Im E, Chung HY and Kim ND: HS-1793, a
resveratrol analogue, downregulates the expression of
hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human
breast cancer cells in a nude mouse xenograft model. Int J Oncol.
51:715–723. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Masoud GN and Li W: HIF-1α pathway: Role,
regulation and intervention for cancer therapy. Acta Pharm Sin B.
5:378–389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choudhry H and Harris AL: Advances in
hypoxia-inducible factor biology. Cell Metab. 27:281–298. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Semenza GL: HIF-1: Upstream and downstream
of cancer metabolism. Curr Opin Genet Dev. 20:51–56. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Soga T: Cancer metabolism: Key players in
metabolic reprogramming. Cancer Sci. 104:275–281. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meijer TW, Kaanders JH, Span PN and
Bussink J: Targeting hypoxia, HIF-1, and tumor glucose metabolism
to improve radiotherapy efficacy. Clin Cancer Res. 18:5585–5594.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fan C, Tang Y, Wang J, Xiong F, Guo C,
Wang Y, Zhang S, Gong Z, Wei F, Yang L, et al: Role of long
non-coding RNAs in glucose metabolism in cancer. Mol Cancer.
16:1302017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang S, Wang X, Weng Z, Zhang S, Ning H
and Li B: Expression and role of microRNA 18b and hypoxia inducible
factor-1α in placental tissues of preeclampsia patients. Exp Ther
Med. 14:4554–4560. 2017.PubMed/NCBI
|
|
22
|
Li B, Qiu B, Lee DS, Walton ZE, Ochocki
JD, Mathew LK, Mancuso A, Gade TP, Keith B, Nissim I and Simon MC:
Fructose-1,6-bisphosphatase opposes renal carcinoma progression.
Nature. 513:251–255. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sato R, Semba T, Saya H and Arima Y:
Concise review: Stem cells and epithelial-mesenchymal transition in
cancer: Biological implications and therapeutic targets. Stem
Cells. 34:1997–2007. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
May CD, Sphyris N, Evans KW, Werden SJ,
Guo W and Mani SA: Epithelial-mesenchymal transition and cancer
stem cells: A dangerously dynamic duo in breast cancer progression.
Breast Cancer Res. 13:2022011. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi S, Zhao J, Wang J, Mi D and Ma Z: HPIP
silencing inhibits TGF-β1-induced EMT in lung cancer cells. Int J
Mol Med. 39:479–483. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dong C, Yuan T, Wu Y, Wang Y, Fan TW,
Miriyala S, Lin Y, Yao J, Shi J, Kang T, et al: Loss of FBP1 by
Snail-mediated repression provides metabolic advantages in
basal-like breast cancer. Cancer Cell. 23:316–331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jourdan-Le Saux C, Tronecker H, Bogic L,
Bryant-Greenwood GD, Boyd CD and Csiszar K: The LOXL2 gene encodes
a new lysyl oxidase-like protein and is expressed at high levels in
reproductive tissues. J Biol Chem. 274:12939–12944. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Choi SE, Jeon N, Choi HY, Shin JI, Jeong
HJ and Lim BJ: Lysyl oxidase-like 2 is expressed in kidney tissue
and is associated with the progression of tubulointerstitial
fibrosis. Mol Med Rep. 16:2477–2482. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu L and Zhu Y: The function and
mechanisms of action of LOXL2 in cancer (Review). Int J Mol Med.
36:1200–1204. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cuevas EP, Eraso P, Mazón MJ, Santos V,
Moreno-Bueno G, Cano A and Portillo F: LOXL2 drives
epithelial-mesenchymal transition via activation of IRE1-XBP1
signalling pathway. Sci Rep. 7:449882017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hutchinson JH, Rowbottom MW, Lonergan D,
Darlington J, Prodanovich P, King CD, Evans JF and Bain G: Small
molecule lysyl Oxidase-like 2 (LOXL2) inhibitors: The
identification of an inhibitor selective for LOXL2 over LOX. ACS
Med Chem Lett. 8:423–427. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Peinado H, Del Carmen Iglesias-de la Cruz
M, Olmeda D, Csiszar K, Fong KS, Vega S, Nieto MA, Cano A and
Portillo F: A molecular role for lysyl oxidase-like 2 enzyme in
snail regulation and tumor progression. EMBO J. 24:3446–3458. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chitty JL, Setargew YFI and Cox TR:
Targeting the lysyl oxidases in tumour desmoplasia. Biochem Soc
Trans. 47:1661–1678. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Leung L, Niculescu-Duvaz D, Smithen D,
Lopes F, Callens C, McLeary R, Saturno G, Davies L, Aljarah M,
Brown M, et al: Anti-metastatic Inhibitors of Lysyl Oxidase (LOX):
Design and Structure-activity relationships. J Med Chem.
62:5863–5884. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tang H, Leung L, Saturno G, Viros A, Smith
D, Di Leva G, Morrison E, Niculescu-Duvaz D, Lopes F, Johnson L, et
al: Lysyl oxidase drives tumour progression by trapping EGF
receptors at the cell surface. Nat Commun. 8:149092017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Smithen DA, Leung LMH, Challinor M,
Lawrence R, Tang H, Niculescu-Duvaz D, Pearce SP, Mcleary R, Lopes
F, Aljarah M, et al: 2-Aminomethylene-5-sulfonylthiazole inhibitors
of Lysyl Oxidase (LOX) and LOXL2 show significant efficacy in
delaying tumor growth. J Med Chem. Sep 4–2019.(Epub ahead of
print). doi: 10.1021/acs.jmedchem.9b01112.
|
|
38
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Harrison SA, Abdelmalek MF, Caldwell S,
Shiffman ML, Diehl AM, Ghalib R, Lawitz EJ, Rockey DC, Schall RA,
Jia C, et al: Simtuzumab is ineffective for patients with bridging
fibrosis or compensated cirrhosis caused by nonalcoholic
steatohepatitis. Gastroenterology. 155:1140–1153. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Altinbas A: A quick overview to the early
phase clinical trials of Simtuzumab®: Are we loosing the
most promising anti-fibrotic product? Med Hypotheses. 108:159–160.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lunt SY and Vander Heiden MG: Aerobic
glycolysis: Meeting the metabolic requirements of cell
proliferation. Annu Rev Cell Dev Biol. 27:441–464. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brault C, Zerbib Y, Delette C, Marc J,
Gruson B, Marolleau JP and Maizel J: The warburg effect as a type B
lactic acidosis in a patient with acute myeloid leukemia: A
diagnostic challenge for clinicians. Front Oncol. 8:2322018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Qu Y, Xiao H, Xiao W, Xiong Z, Hu W, Gao
Y, Ru Z, Wang C, Bao L, Wang K, et al: Upregulation of MIAT
regulates LOXL2 expression by competitively binding MiR-29c in
clear cell renal cell carcinoma. Cell Physiol Biochem.
48:1075–1087. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zaffryar-Eilot S, Marshall D, Voloshin T,
Bar-Zion A, Spangler R, Kessler O, Ghermazien H, Brekhman V,
Suss-Toby E, Adam D, et al: Lysyl oxidase-like-2 promotes tumour
angiogenesis and is a potential therapeutic target in angiogenic
tumours. Carcinogenesis. 34:2370–2379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cheng L, Yu H, Yan N, Lai K and Xiang M:
Hypoxia-inducible factor-1α target genes contribute to retinal
neuroprotection. Front Cell Neurosci. 11:202017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shi L, He C, Li Z, Wang Z and Zhang Q:
FBP1 modulates cell metabolism of breast cancer cells by inhibiting
the expression of HIF-1α. Neoplasma. 64:535–542. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lee K and Kim HM: A novel approach to
cancer therapy using PX-478 as a HIF-1α inhibitor. Arch Pharm Res.
34:1583–1585. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Barone C, Koeberle D, Metselaar H, Parisi
G, Sansonno D and Spinzi G: Multidisciplinary approach for HCC
patients: Hepatology for the oncologists. Ann Oncol. 24 (Suppl
2):ii15–ii23. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ahn SG, Dong SM, Oshima A, Kim WH, Lee HM,
Lee SA, Kwon SH, Lee JH, Lee JM, Jeong J, et al: LOXL2 expression
is associated with invasiveness and negatively influences survival
in breast cancer patients. Breast Cancer Res Treat. 141:89–99.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bais MV and Goldring MB: LOXL2 as a
protective in osteoarthritis cartilage. Aging (Albany NY).
9:2024–2025. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Atala A: Re: Tumour-suppressive
MicroRNA-29s directly regulate LOXL2 expression and inhibit cancer
cell migration and invasion in renal cell carcinoma. J Urol.
195:16222016. View Article : Google Scholar
|
|
52
|
Ye Y, Song YN, He SF, Zhuang JH, Wang GY
and Xia W: GINS2 promotes cell proliferation and inhibits cell
apoptosis in thyroid cancer by regulating CITED2 and LOXL2. Cancer
Gene Ther. 26:103–113. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Park JS, Lee JH, Lee YS, Kim JK, Dong SM
and Yoon DS: Emerging role of LOXL2 in the promotion of pancreas
cancer metastasis. Oncotarget. 7:42539–42552. 2016.PubMed/NCBI
|
|
54
|
Wu L, Zhang Y, Zhu Y, Cong Q, Xiang Y and
Fu L: The effect of LOXL2 in hepatocellular carcinoma. Mol Med Rep.
14:1923–1932. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Barker HE, Chang J, Cox TR, Lang G, Bird
D, Nicolau M, Evans HR, Gartland A and Erler JT: LOXL2-mediated
matrix remodeling in metastasis and mammary gland involution.
Cancer Res. 71:1561–1572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Cuevas EP, Moreno-Bueno G, Canesin G,
Santos V, Portillo F and Cano A: LOXL2 catalytically inactive
mutants mediate epithelial-to-mesenchymal transition. Biol Open.
3:129–137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Liu X, Wang X, Zhang J, Lam EK, Shin VY,
Cheng AS, Yu J, Chan FK, Sung JJ and Jin HC: Warburg effect
revisited: An epigenetic link between glycolysis and gastric
carcinogenesis. Oncogene. 29:442–450. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wong CC, Tse AP, Huang YP, Zhu YT, Chiu
DK, Lai RK, Au SL, Kai AK, Lee JM, Wei LL, et al: Lysyl
oxidase-like 2 is critical to tumor microenvironment and metastatic
niche formation in hepatocellular carcinoma. Hepatology.
60:1645–1658. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wang M, Zhao X, Zhu D, Liu T, Liang X, Liu
F, Zhang Y, Dong X and Sun B: HIF-1α promoted vasculogenic mimicry
formation in hepatocellular carcinoma through LOXL2 up-regulation
in hypoxic tumor microenvironment. J Exp Clin Cancer Res.
36:602017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ninomiya G, Yamada S, Hayashi M, Takeda S,
Suenaga M, Takami H, Kanda M, Iwata N, Niwa Y, Tanaka C, et al:
Significance of Lysyl oxidaselike 2 gene expression on the
epithelial-mesenchymal status of hepatocellular carcinoma. Oncol
Rep. 39:2664–2672. 2018.PubMed/NCBI
|
|
61
|
Yang MH, Chen CL, Chau GY, Chiou SH, Su
CW, Chou TY, Peng WL and Wu JC: Comprehensive analysis of the
independent effect of twist and snail in promoting metastasis of
hepatocellular carcinoma. Hepatology. 50:1464–1474. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wu TJ, Chang SS, Li CW, Hsu YH, Chen TC,
Lee WC, Yeh CT and Hung MC: Severe hepatitis promotes
hepatocellular carcinoma recurrence via NF-κB pathway-mediated
epithelial-mesenchymal transition after resection. Clin Cancer Res.
22:1800–1812. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Hirata H, Sugimachi K, Komatsu H, Ueda M,
Masuda T, Uchi R, Sakimura S, Nambara S, Saito T, Shinden Y, et al:
Decreased expression of Fructose-1,6-bisphosphatase associates with
glucose metabolism and tumor progression in hepatocellular
carcinoma. Cancer Res. 76:3265–3276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yang J, Jin X, Yan Y, Shao Y, Pan Y,
Roberts LR, Zhang J, Huang H and Jiang J: Inhibiting histone
deacetylases suppresses glucose metabolism and hepatocellular
carcinoma growth by restoring FBP1 expression. Sci Rep.
7:438642017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Yang J, Wang C, Zhao F, Luo X, Qin M,
Arunachalam E, Ge Z, Wang N, Deng X, Jin G, et al: Loss of FBP1
facilitates aggressive features of hepatocellular carcinoma cells
through the Warburg effect. Carcinogenesis. 38:134–143.
2017.PubMed/NCBI
|
|
66
|
Jiang H, Zhou Z, Jin S, Xu K, Zhang H and
Xu J, Sun Q, Wang J and Xu J: PRMT9 promotes hepatocellular
carcinoma invasion and metastasis via activating
PI3K/Akt/GSK-3β/Snail signaling. Cancer Sci. 109:1414–1427. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Liu GM, Li Q, Zhang PF, Shen SL, Xie WX,
Chen B, Wu J, Hu WJ, Huang XY and Peng BG: Restoration of FBP1
suppressed Snail-induced epithelial to mesenchymal transition in
hepatocellular carcinoma. Cell Death Dis. 9:11322018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Chen Z, Zuo X, Zhang Y, Han G, Zhang L, Wu
J and Wang X: MiR-3662 suppresses hepatocellular carcinoma growth
through inhibition of HIF-1α-mediated Warburg effect. Cell Death
Dis. 9:5492018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Courtnay R, Ngo DC, Malik N, Ververis K,
Tortorella SM and Karagiannis TC: Cancer metabolism and the Warburg
effect: The role of HIF-1 and PI3K. Mol Biol Rep. 42:841–851. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Takano S, Ishikawa E, Matsuda M, Sakamoto
N, Akutsu H, Yamamoto T and Matsumura A: The anti-angiogenic role
of soluble-form VEGF receptor in malignant gliomas. Int J Oncol.
50:515–524. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zhu AX, Duda DG, Sahani DV and Jain RK:
HCC and angiogenesis: Possible targets and future directions. Nat
Rev Clin Oncol. 8:292–301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yang ZF and Poon RT: Vascular changes in
hepatocellular carcinoma. Anat Rec (Hoboken). 291:721–734. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Berretta M, Rinaldi L, Di Benedetto F,
Lleshi A, De Re V, Facchini G, De Paoli P and Di Francia R:
Angiogenesis inhibitors for the treatment of hepatocellular
carcinoma. Front Pharmacol. 7:4282016. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Mossenta M, Busato D, Baboci L, Cintio FD,
Toffoli G and Bo MD: New insight into therapies targeting
angiogenesis in hepatocellular carcinoma. Cancers (Basel). 11(pii):
E10862019. View Article : Google Scholar : PubMed/NCBI
|
